BRAF and non-small cell lung carcinoma: In accordance with these studies, Gautschi et al. demonstrated the efficacy of different targeted therapies (vemurafenib, dabrafenib, sorafenib) in advanced-stage NSCLC patients harboring BRAF mutations [126].